Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity

被引：224
作者：
Gerhard, Danielle M. [1 ]
Wohleb, Eric S. [2 ]
Duman, Ronald S. [2 ]
机构：
[1] Yale Univ, Dept Psychol, New Haven, CT 06511 USA
[2] Yale Univ, Mol Psychiat, New Haven, CT 06711 USA
来源：
DRUG DISCOVERY TODAY | 2016年 / 21卷 / 03期
关键词：
METHYL-D-ASPARTATE; MEDIAL PREFRONTAL CORTEX; NMDA RECEPTOR BLOCKADE; PROOF-OF-CONCEPT; ANTIDEPRESSANT EFFICACY; PROTEIN EXPRESSION; MAJOR DEPRESSION; PARTIAL AGONIST; D-CYCLOSERINE; KETAMINE;
D O I：
10.1016/j.drudis.2016.01.016
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects. Recent efforts have been directed towards investigating rapid-acting agents that reverse the behavioral and neuronal deficits of chronic stress and depression, notably the glutamate NMDA receptor antagonist ketamine. The cellular mechanisms underlying the rapid antidepressant actions of ketamine and related agents are discussed, as well as novel, selective glutamatergic receptor targets that are safer and have fewer side effects.
引用
收藏
页码：454 / 464
页数：11
相关论文
共 100 条
  • [21] Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels
    Drevets, WC
    Price, JL
    Bardgett, ME
    Reich, T
    Todd, RD
    Raichle, ME
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 71 (03) : 431 - 447
  • [22] Duman C., 2015, GLYX13 INCREASES MTO
  • [23] Duman RS, 2014, DIALOGUES CLIN NEURO, V16, P11
  • [24] Synaptic Dysfunction in Depression: Potential Therapeutic Targets
    Duman, Ronald S.
    Aghajanian, George K.
    [J]. SCIENCE, 2012, 338 (6103) : 68 - 72
  • [25] Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents
    Duman, Ronald S.
    Voleti, Bhavya
    [J]. TRENDS IN NEUROSCIENCES, 2012, 35 (01) : 47 - 56
  • [26] Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior
    Dwyer, Jason M.
    Maldonado-Aviles, Jaime G.
    Lepack, Ashley E.
    DiLeone, Ralph J.
    Duman, Ronald S.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (19) : 6188 - 6193
  • [27] Dwyer Jason M, 2013, J Mol Psychiatry, V1, P15, DOI 10.1186/2049-9256-1-15
  • [28] mTOR activation is required for the antidepressant effects of mGluR2/3 blockade
    Dwyer, Jason M.
    Lepack, Ashley E.
    Duman, Ronald S.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (04) : 429 - 434
  • [29] The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
    Egan, MF
    Kojima, M
    Callicott, JH
    Goldberg, TE
    Kolachana, BS
    Bertolino, A
    Zaitsev, E
    Gold, B
    Goldman, D
    Dean, M
    Lu, B
    Weinberger, DR
    [J]. CELL, 2003, 112 (02) : 257 - 269
  • [30] Antidepressant treatment history as a predictor of response to scopolamine: clinical implications
    Ellis, Jessica S.
    Zarate, Carlos A., Jr.
    Luckenbaugh, David A.
    Furey, Maura L.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2014, 162 : 39 - 42
12345678910